article Open Access
Imidazopyrimidines, potent inhibitors of p38 MAP kinase
Bioorganic & Medicinal Chemistry Letters · 2003 · Vol. 13(3) · pp. 347–350
Kenneth C. Rupert✉(Johnson & Johnson (United States))James R. Henry✉(Johnson & Johnson (United States))John H. Dodd(Johnson & Johnson (United States))Scott Wadsworth(Johnson & Johnson (United States))Druie Cavender(Johnson & Johnson (United States))Gilbert C. Olini(Johnson & Johnson (United States))Bohumila Fahmy(Johnson & Johnson (United States))John J. Siekierka(Johnson & Johnson (United States))
Melanoma and MAPK PathwaysCytokine Signaling Pathways and InteractionsSynthesis and biological activityChemistryp38 mitogen-activated protein kinasesRheumatoid arthritisCytokineIn vivoKinaseMitogen-activated protein kinaseArthritisTumor necrosis factor alphaPharmacology
MeSH terms
CatalysisEnzyme InhibitorsImidazolesIndicators and ReagentsPyrimidinesStructure-Activity RelationshipTumor Necrosis Factor-alphaMitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein Kinases
Citations
250
FWCI
1.03
field-weighted impact
References
14
Percentile
75%
vs. same field & year
Citations per year
References
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
Journal of Pharmacology and Experimental Therapeutics · 1996 · 499 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.